Medibio Ltd
ASX:MEB
Intrinsic Value
Medibio Ltd. engages in the clinical research, product development and early stage commercialization of a mental health technology. [ Read More ]
The intrinsic value of one MEB stock under the Base Case scenario is 0.001 AUD. Compared to the current market price of 0.02 AUD, Medibio Ltd is Overvalued by 96%.
Valuation Backtest
Medibio Ltd
Run backtest to discover the historical profit from buying and selling MEB stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Medibio Ltd
Current Assets | 304.5k |
Cash & Short-Term Investments | 214.1k |
Other Current Assets | 90.4k |
Non-Current Assets | 7.8m |
PP&E | 107.5k |
Intangibles | 7.6m |
Other Non-Current Assets | 15.2k |
Current Liabilities | 1.8m |
Accounts Payable | 1.4m |
Accrued Liabilities | 143.1k |
Other Current Liabilities | 234.9k |
Earnings Waterfall
Medibio Ltd
Revenue
|
963.8k
AUD
|
Cost of Revenue
|
-160
AUD
|
Gross Profit
|
963.6k
AUD
|
Operating Expenses
|
-2.8m
AUD
|
Operating Income
|
-1.8m
AUD
|
Other Expenses
|
-1.3m
AUD
|
Net Income
|
-3.1m
AUD
|
Free Cash Flow Analysis
Medibio Ltd
MEB Profitability Score
Profitability Due Diligence
Medibio Ltd's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
Medibio Ltd's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
MEB Solvency Score
Solvency Due Diligence
Medibio Ltd's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Medibio Ltd's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MEB Price Targets Summary
Medibio Ltd
Shareholder Return
MEB Price
Medibio Ltd
Average Annual Return | -28.38% |
Standard Deviation of Annual Returns | 19.03% |
Max Drawdown | -95% |
Market Capitalization | 122m AUD |
Shares Outstanding | 6 100 743 763 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Medibio Ltd. engages in the clinical research, product development and early stage commercialization of a mental health technology. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2001-01-29. The firm offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company offers a software called MEBsleep, a medical device that analyses Electroencephalogram (EEG) and Electrocardiogram (ECG) data collected during polysomnography to verify sleep stages and heart rate variability (HRV) in patients suffering from primary or secondary sleep disturbances. The Company’s subsidiaries include Bioprospect Australia Pty Ltd, Australian Phytochemicals Pty Ltd, BioProspect America Pty Ltd, Medibio Limited USA, Invatec Health Pty Ltd and Annapanna Pty Ltd.
Contact
IPO
Employees
Officers
The intrinsic value of one MEB stock under the Base Case scenario is 0.001 AUD.
Compared to the current market price of 0.02 AUD, Medibio Ltd is Overvalued by 96%.